Seeking AlphaCodex · 实盘不做把握 3/10
北京时间·🕒 发布 05:26:01时区推断·⟳ 抓取 05:27:15·⚡ 决策 07-28 05:27:44 +29s·91.9 天前
GeoVax二季度每股亏损好于预期但BARDA合同收入已归零
这是例行财报快讯，EPS亏损幅度好于预期，但正文同时说明2026年已无BARDA合同收入确认。
📄 原文Seeking Alpha↗ 原文
GeoVax GAAP EPS of -$0.97 beats by $1.18
- GeoVax press release (GOVX): Q2 GAAP EPS of -$0.97 beats by $1.18. - During the three-month and six-month periods end…
不做 GeoVax（GOVX.US）
例行财报快讯，EPS beat缺少收入或管线新增催化；BARDA终止合同为旧事实复述，无法形成正期望同向交易。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-27 · 扩散 medium · price-in 风险 medium ↗
关键理由
- 这是例行财报快讯，EPS亏损幅度好于预期，但正文同时说明2026年已无BARDA合同收入确认。
- BARDA终止合同的关键事实发生在2025年4月，本条主要是财报口径复述，不是新的订单、获批或商业化催化。
- 小型疫苗公司短线交易需要管线、资金或合同新增事实；本条没有给出可量化新增收入或催化节点。
主要风险
- 财报标题的EPS beat可能来自费用节奏或会计口径，缺少收入增长与管线进展支撑。
原文全文
展开原文 · 558 字
- GeoVax press release (GOVX): Q2 GAAP EPS of -$0.97 beats by $1.18.
- During the three-month and six-month periods ending June 30, 2025, GeoVax reported $852,282 and $2,489,145 of government contract revenues associated with the company's contract with the Biomedical Advanced Research and Development Authority for its GEO-CM04S1 COVID-19 vaccine program. In April 2025, GeoVax received notification that BARDA determined to terminate the contract for convenience to the government. Accordingly, no comparable revenue was recognized during the 2026 period.
- During the three-month and six-month periods ending June 30, 2025, GeoVax reported $852,282 and $2,489,145 of government contract revenues associated with the company's contract with the Biomedical Advanced Research and Development Authority for its GEO-CM04S1 COVID-19 vaccine program. In April 2025, GeoVax received notification that BARDA determined to terminate the contract for convenience to the government. Accordingly, no comparable revenue was recognized during the 2026 period.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。